Bio-Rad Laboratories (NYSE:BIO) Hits New 12-Month High – Here’s Why

Bio-Rad Laboratories, Inc. (NYSE:BIO)’s share price hit a new 52-week high on Tuesday . The company traded as high as $386.67 and last traded at $386.4110, with a volume of 97330 shares changing hands. The stock had previously closed at $381.76.

Key Stories Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to $9.71 from $9.42 and increased its Q1 2028 estimate to $2.26 from $1.96, suggesting stronger near-term earnings expectations. Bio-Rad Laboratories stock information
• Neutral Sentiment: The revisions leave Zacks’ current full-year estimate around $9.14 per share, below the broader consensus estimate of approximately $9.28 referenced in the company’s earnings data. The unchanged Hold rating provides no new analyst catalyst.
• Negative Sentiment: Zacks reduced several longer-term forecasts: FY2027 EPS to $9.02 from $9.30, FY2028 EPS to $9.26 from $9.87, Q3 2027 EPS to $2.25 from $2.39, Q4 2027 EPS to $2.32 from $2.48, and Q2 2028 EPS to $2.32 from $2.46. These cuts imply more cautious expectations for earnings growth beyond FY2026.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wells Fargo & Company raised their price objective on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Citigroup increased their target price on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on shares of Bio-Rad Laboratories from $320.00 to $370.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings upgraded Bio-Rad Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $343.33.

Bio-Rad Laboratories Stock Up 0.2%

The company has a market capitalization of $10.46 billion, a price-to-earnings ratio of 47.43 and a beta of 1.06. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average price of $322.01 and a two-hundred day moving average price of $294.60.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $2.62 EPS for the quarter, topping the consensus estimate of $1.75 by $0.87. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%.The business had revenue of $651.00 million for the quarter, compared to analysts’ expectations of $623.99 million. During the same quarter in the previous year, the firm posted $2.61 earnings per share. The company’s revenue was down .1% compared to the same quarter last year. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 9.28 earnings per share for the current year.

Institutional Trading of Bio-Rad Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System grew its holdings in Bio-Rad Laboratories by 27,700.0% during the 2nd quarter. California State Teachers Retirement System now owns 6,097,105 shares of the medical research company’s stock worth $1,790,171,000 after acquiring an additional 6,075,173 shares in the last quarter. First Eagle Investment Management LLC raised its position in shares of Bio-Rad Laboratories by 2.0% during the 4th quarter. First Eagle Investment Management LLC now owns 2,570,473 shares of the medical research company’s stock valued at $778,828,000 after acquiring an additional 50,154 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Bio-Rad Laboratories by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock valued at $303,637,000 after purchasing an additional 12,251 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Bio-Rad Laboratories by 18.2% in the 4th quarter. Capital Research Global Investors now owns 494,472 shares of the medical research company’s stock worth $149,820,000 after buying an additional 76,117 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Bio-Rad Laboratories by 1.7% during the third quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after acquiring an additional 7,754 shares during the period. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.